Indoleamine 2,3-dioxygenase in immune suppression and cancer

Current Cancer Drug Targets

Volumn 7, Issue 1, 2007, Pages 31-40

  Muller, Alexander J ^a   Prendergast, George C ^a,b  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

IDO; Immune suppression; T cells; Tolerance; Tumor immunology

Indexed keywords

1 METHYL TRYPTOPHAN; ABATACEPT; ACETYLSALICYLIC ACID; AMPHIPHYSIN; ANTINEOPLASTIC AGENT; CD28 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INDOMETACIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRIC OXIDE; PHENYLBUTAZONE; PROTEIN KINASE INHIBITOR; STAT1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN; UNCLASSIFIED DRUG;

BIN1 GENE; CANCER; CANCER IMMUNOLOGY; CELLULAR IMMUNITY; DRUG INHIBITION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; GENE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DENDRITIC CELLS; ENZYME INHIBITORS; HUMANS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; NEOPLASMS;

EID: 33847388907     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907780006896     Document Type: Review

References (106)

1. Sugimoto, H.; Oda, S. I.; Otsuki, T.; Hino, T.; Yoshida, T.; Shiro, Y. Crystal structure of human indoleamine 2,3-dioxygenase: Catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc. Natl. Acad. Sci. USA 2006, 103, 2611-2616.
2. Kadoya, A.; Tone, S.; Maeda, H.; Minatogawa, Y.; Kido, R. Gene structure of human indoleamine 2,3-dioxygenase. Biochem. Biophys. Res. Commun. 1992, 189, 530-536.
3. Najfeld, V.; Menninger, J.; Muhleman, D.; Comings, D. E.; Gupta, S. L. Localization of indoleamine 2,3-dioxygenase gene (INDO) to chromosome 8p12->p11 by fluorescent in situ hybridization. Cytogenet. Cell. Genet. 1993, 64, 231-232.
4. Hayaishi, O. Properties and function of indoleamine 2,3-dioxygenase. J. Biochem. (Tokyo) 1976, 79, 13P-21P.
5. Shimizu, T.; Nomiyama, S.; Hirata, F.; Hayaishi, O. Indoleamine 2,3-dioxygenase. Purification and some properties. J. Biol. Chem. 1978, 253, 4700-4706.
6. Rose, D.; Sheff, M. D. Tryptophan metabolism in carcinoma of the breast. Lancet 1967, 1, 239-241.
7. Yasui, H.; Takai, K.; Yoshida, R.; Hayaishi, O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurence in cancer patients. Proc. Natl. Acad. Sci. USA 1986, 83, 6622-6626.
8. Ozaki, Y.; Edelstein, M. P.; Duch, D. S. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc. Natl. Acad. Sci. USA 1988, 85, 1242-1246.
9. Mellor, A. L.; Munn, D. H. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol. Today 1999, 20, 469-473.
10. Munn, D. H.; Shafizadeh, E.; Attwood, J. T.; Bondarev, I.; Pashine, A.; Mellor, A. L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 1999, 189, 1363-1372.
11. Cady, S. G.; Sono, M. 1-methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL- alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL- alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch. Biochem. Biophys. 1991, 291, 326-333.
12. Munn, D. H.; Zhou, M.; Attwood, J. T.; Bondarev, I.; Conway, S. J.; Marshall, B.; Brown, C.; Mellor, A. L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281, 1191-1193.
13. Mellor, A. L.; Sivakumar, J.; Chandler, P. K. S.; Molina, H.; Mao, D.; Munn, D. H. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat. Immunol. 2001, 2, 64-68.
14. Braun, D.; Longman, R. S.; Albert, M. L. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005, 106, 2375-2381.
15. Sayama, S.; Yoshida, R.; Oku, T.; Imanishi, J.; Kishida, T.; Hayaishi, O. Inhibition of interferon-mediated induction of indoleamine 2,3-dioxygenase in mouse lung by inhibitors of prostaglandin biosynthesis. Proc. Natl. Acad. Sci. USA 1981, 78, 7327-7330.
16. Marshall, B.; Keskin, D. B.; Mellor, A. L. Regulation of prostaglandin synthesis and cell adhesion by a tryptophan catabolizing enzyme. BMC Biochem. 2001, 2, 5.
17. Fujigaki, S.; Saito, K.; Takemura, M.; Maekawa, N.; Yamada, Y.; Wada, H.; Seishima, M. L-tryptophan-L-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene- deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase. Infect. Immun. 2002, 70, 779-786.
18. Fujigaki, H.; Saito, K.; Lin, F.; Fujigaki, S.; Takahashi, K.; Martin, B. M.; Chen, C. Y.; Masuda, J.; Kowalak, J.; Takikawa, O.; Seishima, M.; Markey, S. P. Nitration and inactivation of IDO by peroxynitrite. J. Immunol. 2006, 176, 372-379.
19. Chiarugi, A.; Rovida, E.; Dello Sbarba, P.; Moroni, F. Tryptophan availability selectively limits NO-synthase induction in macrophages. J. Leukoc. Biol. 2003, 73, 172-177.
20. Fallarino, F.; Bianchi, R.; Orabona, C.; Vacca, C.; Belladonna, M. L.; Fioretti, M. C.; Serreze, D. V.; Grohmann, U.; Puccetti, P. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J. Exp. Med. 2004, 200, 1051-1062.
21. Yoeli-Lerner, M.; Toker, A. Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 2006, 5, 603-605.
22. Yuan, W.; Collado-Hidalgo, A.; Yufit, T.; Taylor, M.; Varga, J. Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor-beta: selective inhibition of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. J. Cell. Physiol. 1998, 177, 174-186.
23. Mellor, A. Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem. Biophys. Res. Commun. 2005, 338, 20-24.
24. Kronin, V.; Winkel, K.; Suss, G.; Kelso, A.; Heath, W.; Kirberg, J.; von Boehmer, H.; Shortman, K. A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production. J. Immunol. 1996, 157, 3819-3827.
25. Belz, G. T.; Behrens, G. M.; Smith, C. M.; Miller, J. F.; Jones, C.; Lejon, K.; Fathman, C. G.; Mueller, S. N.; Shortman, K.; Carbone, F. R.; Heath, W. R. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J. Exp. Med. 2002, 196, 1099-1104.
26. Homann, D.; Jahreis, A.; Wolfe, T.; Hughes, A.; Coon, B.; van Stipdonk, M. J.; Prilliman, K. R.; Schoenberger, S. P.; von Herrath, M. G. CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells. Immunity 2002, 16, 403-415.
27. Wakkach, A.; Fournier, N.; Brun, V.; Breittmayer, J. P.; Cottrez, F.; Groux, H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003, 18, 605-617.
28. Baban, B.; Hansen, A. M.; Chandler, P. R.; Manlapat, A.; Bingaman, A.; Kahler, D. J.; Munn, D. H.; Mellor, A. L. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int. Immunol. 2005, 17, 909-919.
29. Ghiringhelli, F.; Puig, P. E.; Roux, S.; Parcellier, A.; Schmitt, E.; Solary, E.; Kroemer, G.; Martin, F.; Chauffert, B.; Zitvogel, L. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 2005, 202, 919-929.
30. Liu, Y.; Bi, X.; Xu, S.; Xiang, J. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses. Cancer Res. 2005, 65, 4955-4962.
31. Munn, D. H.; Sharma, M. D.; Hou, D.; Baban, B.; Lee, J. R.; Antonia, S. J.; Messina, J. L.; Chandler, P.; Koni, P. A.; Mellor, A. L. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 2004, 114, 280-290.
32. Mellor, A. L.; Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 2004, 4, 762-774.
33. Moser, M. Dendritic cells in immunity and tolerance-do they display opposite functions? Immunity 2003, 19, 5-8.
34. Salomon, B.; Lenschow, D. J.; Rhee, L.; Ashourian, N.; Singh, B.; Sharpe, A.; Bluestone, J. A. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12, 431-440.
35. Lohr, J.; Knoechel, B.; Jiang, S.; Sharpe, A. H.; Abbas, A. K. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat. Immunol. 2003, 4, 664-669.
36. Liang, S.; Alard, P.; Zhao, Y.; Parnell, S.; Clark, S. L.; Kosiewicz, M. M. Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J. Exp. Med. 2005, 201, 127-137.
37. Grohmann, U.; Orabona, C.; Fallarino, F.; Vacca, C.; Calcinaro, F.; Falorni, A.; Candeloro, P.; Belladonna, M. L.; Bianchi, R.; Fioretti, M. C.; Puccetti, P. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 2002, 3, 1097-1101.
38. Fallarino, F.; Grohmann, U.; Hwang, K. W.; Orabona, C.; Vacca, C.; Bianchi, R.; Belladonna, M. L.; Fioretti, M. C.; Alegre, M. L.; Puccetti, P. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 2003, 4, 1206-1212.
39. Munn, D. H.; Sharma, M. D.; Lee, J. R.; Jhaver, K. G.; Johnson, T. S.; Keskin, D. B.; Marshall, B.; Chandler, P.; Antonia, S. J.; Burgess, R.; Slingluff, C. L., Jr.; Mellor, A. L. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002, 297, 1867-1870.
40. Bluestone, J. A.; Abbas, A. K. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 2003, 3, 253-257.
41. Piccirillo, C. A.; Shevach, E. M. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol. 2004, 16, 81-88.
42. Sakaguchi, S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004, 22, 531-562.
43. Wood, K. J.; Sakaguchi, S. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 2003, 3, 199-210.
44. Aluvihare, V. R.; Kallikourdis, M.; Betz, A. G. Regulatory T cells mediate maternal tolerance to the fetus. Nat. Immunol. 2004, 5, 266-271.
45. Zenclussen, A. C.; Gerlof, K.; Zenclussen, M. L.; Sollwedel, A.; Bertoja, A. Z.; Ritter, T.; Kotsch, K.; Leber, J.; Volk, H. D. Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. Am. J. Pathol. 2005, 166, 811-822.
46. Grohmann, U.; Fallarino, F.; Puccetti, P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 2003, 24, 242-248.
47. Mellor, A. L.; Baban, B.; Chandler, P.; Marshall, B.; Jhaver, K.; Hansen, A.; Koni, P. A.; Iwashima, M.; Munn, D. H. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 2003, 171, 1652-1655.
48. Terness, P.; Chuang, J. J.; Opelz, G. The immunoregulatory role of IDO-producing human dendritic cells revisited. Trends Immunol. 2006, 27, 68-73.
49. Mellor, A. L.; Chandler, P.; Baban, B.; Hansen, A. M.; Marshall, B.; Pihkala, J.; Waldmann, H.; Cobbold, S.; Adams, E.; Munn, D. H. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol. 2004, 16, 1391-1401.
50. Mellor, A. L.; Baban, B.; Chandler, P. R.; Manlapat, A.; Kahler, D. J.; Munn, D. H. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J. Immunol. 2005, 175, 5601-5605.
51. Fallarino, F.; Asselin-Paturel, C.; Vacca, C.; Bianchi, R.; Gizzi, S.; Fioretti, M. C.; Trinchieri, G.; Grohmann, U.; Puccetti, P. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J. Immunol. 2004, 173, 3748-3754.
52. Fallarino, F.; Orabona, C.; Vacca, C.; Bianchi, R.; Gizzi, S.; Asselin-Paturel, C.; Fioretti, M. C.; Trinchieri, G.; Grohmann, U.; Puccetti, P. Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. Int. Immunol. 2005, 17, 1429-1438.
53. Wingender, G.; Garbi, N.; Schumak, B.; Jungerkes, F.; Endl, E.; von Bubnoff, D.; Steitz, J.; Striegler, J.; Moldenhauer, G.; Tuting, T.; Heit, A.; Huster, K. M.; Takikawa, O.; Akira, S.; Busch, D. H.; Wagner, H.; Hammerling, G. J.; Knolle, P. A.; Limmer, A. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 2006, 36, 12-20.
54. Sharpe, A. H.; Freeman, G. J. The B7-CD28 superfamily. Nat. Rev. Immunol. 2002, 2, 116-126.
55. Grohmann, U.; Bianchi, R.; Belladonna, M. L.; Silla, S.; Fallarino, F.; Fioretti, M. C.; Puccetti, P. IFN-gamma inhibits presentation of a tumor/self peptide by CD8 alpha- dendritic cells via potentiation of the CD8 alpha+ subset. J. Immunol. 2000, 165, 1357-1363.
56. Grohmann, U.; Bianchi, R.; Belladonna, M. L.; Vacca, C.; Silla, S.; Ayroldi, E.; Fioretti, M. C.; Puccetti, P. IL-12 acts selectively on CD8 alpha- dendritic cells to enhance presentation of a tumor peptide in vivo. J. Immunol. 1999, 163, 3100-3105.
57. Fallarino, F.; Vacca, C.; Orabona, C.; Belladonna, M. L.; Bianchi, R.; Marshall, B.; Keskin, D. B.; Mellor, A. L.; Fioretti, M. C.; Grohmann, U.; Puccetti, P. Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int. Immunol. 2002, 14, 65-68.
58. Grohmann, U.; Fallarino, F.; Bianchi, R.; Belladonna, M. L.; Vacca, C.; Orabona, C.; Uyttenhove, C.; Fioretti, M. C.; Puccetti, P. IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase. J. Immunol. 2001, 167, 708-714.
59. Grohmann, U.; Bianchi, R.; Orabona, C.; Fallarino, F.; Vacca, C.; Micheletti, A.; Fioretti, M. C.; Puccetti, P. Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J. Immunol. 2003, 171, 2581-2587.
60. Orabona, C.; Grohmann, U.; Belladonna, M. L.; Fallarino, F.; Vacca, C.; Bianchi, R.; Bozza, S.; Volpi, C.; Salomon, B. L.; Fioretti, M. C.; Romani, L.; Puccetti, P. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat. Immunol. 2004, 5, 1134-1142.
61. Orabona, C.; Belladonna, M. L.; Vacca, C.; Bianchi, R.; Fallarino, F.; Volpi, C.; Gizzi, S.; Fioretti, M. C.; Grohmann, U.; Puccetti, P. Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J. Immunol. 2005, 174, 6582-6586.
62. Orabona, C.; Tomasello, E.; Fallarino, F.; Bianchi, R.; Volpi, C.; Bellocchio, S.; Romani, L.; Fioretti, M. C.; Vivier, E.; Puccetti, P.; Grohmann, U. Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12. Eur. J. Immunol. 2005, 35, 3111-3118.
63. Mantovani, A.; Sozzani, S.; Locati, M.; Allavena, P.; Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23, 549-555.
64. Sinha, P.; Clements, V. K.; Ostrand-Rosenberg, S. Interleukin-13- regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 2005, 65, 11743-11751.
65. Sinha, P.; Clements, V. K.; Ostrand-Rosenberg, S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 2005, 174, 636-645.
66. Hwang, S. L.; Chung, N. P.; Chan, J. K.; Lin, C. L. Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines. Cell Res. 2005, 15, 167-175.
67. Muller, A. J.; Malachowski, W. P.; Prendergast, G. C. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin. Ther. Targets 2005, 9, 831-849.
68. Munn, D. H.; Sharma, M. D.; Baban, B.; Harding, H. P.; Zhang, Y.; Ron, D.; Mellor, A. L. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005, 22, 633-642.
69. Platten, M.; Ho, P. P.; Youssef, S.; Fontoura, P.; Garren, H.; Hur, E. M.; Gupta, R.; Lee, L. Y.; Kidd, B. A.; Robinson, W. H.; Sobel, R. A.; Selley, M. L.; Steinman, L. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005, 310, 850-855.
70. Dunn, G. P.; Old, L. J.; Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21, 137-148.
71. Shankaran, V.; Ikeda, H.; Bruce, A. T.; White, J. M.; Swanson, P. E.; Old, L. J.; Schreiber, R. D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410, 1107-1111.
72. Balkwill, F.; Charles, K. A.; Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7, 211-217.
73. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5, 263-274.
74. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van Den Eynde, B. J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9, 1269-1274.
75. Ge, K.; DuHadaway, J.; Du, W.; Herlyn, M.; Rodeck, U.; Prendergast, G. C. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc. Natl. Acad. Sci. USA 1999, 96, 9689-9694.
76. Ge, K.; DuHadaway, J.; Sakamuro, D.; Wechsler-Reya, R.; Reynolds, C.; Prendergast, G. C. Losses of the tumor suppressor Bin1 in breast carcinoma are frequent and reflect deficits in a programmed cell death capacity. Int. J. Cancer 2000, 85, 376-383.
77. Ge, K.; Minhas, F.; DuHadaway, J.; Mao, N.-C.; Wilson, D.; Sakamuro, D.; Buccafusca, R.; Nelson, P.; Malkowicz, S. B.; Tomaszewski, J. T.; Prendergast, G. C. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int. J. Cancer 2000, 86, 155-161.
78. Tajiri, T.; Liu, X.; Thompson, P. M.; Tanaka, S.; Suita, S.; Zhao, H.; Maris, J. M.; Prendergast, G. C.; Hogarty, M. D. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin. Cancer Res. 2003, 9, 3345-3355.
79. Sakamuro, D.; Elliott, K.; Wechsler-Reya, R.; Prendergast, G. C. BIN1 is a novel MYC-interacting protein with features of a tumor suppressor. Nature Genet. 1996, 14, 69-77.
80. Elliott, K.; Sakamuro, D.; Basu, A.; Du, W.; Wunner, W.; Staller, P.; Gaubatz, S.; Zhang, H.; Prochownik, E.; Eilers, M.; Prendergast, G. C. Bin1 functionally interacts with Myc in cells and inhibits cell proliferation by multiple mechanisms. Oncogene 1999, 18, 3564-3573.
81. Elliott, K.; Ge, K.; Du, W.; Prendergast, G. C. The c-Mycin-teracting adapter protein Bin1 activates a caspase-independent cell death program. Oncogene 2000, 19, 4669-4684.
82. DuHadaway, J. B.; Sakamuro, D.; Ewert, D. L.; Prendergast, G. C. Bin1 mediates apoptosis by c-Myc in transformed primary cells. Cancer Res. 2001, 16, 3151-3156.
83. Galderisi, U.; Di Bernardo, G.; Cipollaro, M.; Jori, F. P.; Piegari, E.; Cascino, A.; Peluso, G.; Melone, M. A. B. Induction of apoptosis and differentiation in neuroblastoma and astrocytoma cells by the overexpression of Bin1, a novel Myc interacting protein. J. Cell. Biochem. 1999, 74, 313-322.
84. Muller, A. J.; DuHadaway, J. B.; Donover, P. S.; Sutanto-Ward, E.; Prendergast, G. C. Targeted deletion of the suppressor gene Bin1/Amphiphysin2 enhances the malignant character of transformed cells. Cancer Biol. Ther. 2004, 3, 1236-1242.
85. Muller, A. J.; DuHadaway, J. B.; Sutanto-Ward, E.; Donover, P. S.; Prendergast, G. C. Inhibition of indoleamine 2,3-dioxygenase, an immunomodulatory target of the tumor suppressor gene Bin1, potentiates cancer chemotherapy. Nat. Med. 2005, 11, 312-319.
86. Peter, B. J.; Kent, H. M.; Mills, I. G.; Vallis, Y.; Butler, P. J.; Evans, P. R.; McMahon, H. T. BAR domains as sensors of membrane curvature: the amphiphysin BAR structure. Science 2003, 303, 495-499.
87. Sparks, A. B.; Hoffman, N. G.; McConnell, S. J.; Fowlkes, D. M.; Kay, B. K. Cloning of ligand targets: systematic isolation of SH3 domain-containing proteins. Nat. Biotech. 1996, 14, 741-744.
88. Kadlec, L.; Pendergast, A.-M. The amphiphysin-like protein 1 (ALP1) interacts functionally with the cABL tyrosine kinase and may play a role in cytoskeletal regulation. Proc. Natl. Acad. Sci. USA 1997, 94, 12390-12395.
89. Ramjaun, A. R.; Micheva, K. D.; Bouchelet, I.; McPherson, P. S. Identification and characterization of a nerve terminal-enriched amphiphysin isoform. J. Biol. Chem. 1997, 272, 16700-16706.
90. Tsutsui, K.; Maeda, Y.; Tsutsui, K.; Seki, S.; Tokunaga, A. cDNA cloning of a novel amphiphysin isoform and tissue-specific expression of its multiple splice variants. Biochem. Biophys. Res. Comm. 1997, 236, 178-183.
91. Butler, M. H.; David, C.; Ochoa, G.-C.; Freyberg, Z.; Daniell, L.; Grabs, D.; Cremona, O.; De Camilli, P. Amphiphysin II (SH3P9; BIN1), a member of the amphiphysin/RVS family, is concentrated in the cortical cytomatrix of axon initial segments and nodes of Ravier in brain and around T tubules in skeletal muscle. J. Cell Biol. 1997, 137, 1355-1367.
92. Wechsler-Reya, R.; Sakamuro, D.; Zhang, J.; Duhadaway, J.; Prendergast, G. C. Structural analysis of the human BIN1 gene: evidence for tissue-specific transcriptional regulation and alternate RNA splicing. J. Biol. Chem. 1997, 272, 31453-31458.
93. DuHadaway, J. B.; Lynch, F. J.; Brisbay, S.; Bueso-Ramos, C.; Troncoso, P.; McDonnell, T.; Prendergast, G. C. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: Diverse sites of nuclear expression and losses in prostate cancer. J. Cell. Biochem. 2003, 88, 635-642.
94. Miaczynska, M.; Christoforidis, S.; Giner, A.; Shevchenko, A.; Uttenweiler-Joseph, S.; Habermann, B.; Wilm, M.; Parton, R. G.; Zerial, M. APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell 2004, 116, 445-456.
95. Okamoto, A.; Nikaido, T.; Ochiai, K.; Takakura, S.; Saito, M.; Aoki, Y.; Ishii, N.; Yanaihara, N.; Yamada, K.; Takikawa, O.; Kawaguchi, R.; Isonishi, S.; Tanaka, T.; Urashima, M. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 2005, 11, 6030-6039.
96. Brandacher, G.; Perathoner, A.; Ladurner, R.; Schneeberger, S.; Obrist, P.; Winkler, C.; Werner, E. R.; Werner-Felmayer, G.; Weiss, H. G.; Gobel, G.; Margreiter, R.; Konigsrainer, A.; Fuchs, D.; Amberger, A. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 2006, 12, 1144-1151.
97. Wolf, A. M.; Wolf, D.; Rumpold, H.; Moschen, A. R.; Kaser, A.; Obrist, P.; Fuchs, D.; Brandacher, G.; Winkler, C.; Geboes, K.; Rutgeerts, P.; Tilg, H. Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin. Immunol. 2004, 113, 47-55.
98. Lee, J. R.; Dalton, R. R.; Messina, J. L.; Sharma, M. D.; Smith, D. M.; Burgess, R. E.; Mazzella, F.; Antonia, S. J.; Mellor, A. L.; Munn, D. H. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab. Invest. 2003, 83, 1457-1466.
99. Astigiano, S.; Morandi, B.; Costa, R.; Mastracci, L.; D'Agostino, A.; Ratto, G. B.; Melioli, G.; Frumento, G. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 2005, 7, 390-396.
100. Friberg, M.; Jennings, R.; Alsarraj, M.; Dessureault, S.; Cantor, A.; Extermann, M.; Mellor, A. L.; Munn, D. H.; Antonia, S. J. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer 2002, 101, 151-155.
101. Baban, B.; Chandler, P.; McCool, D.; Marshall, B.; Munn, D. H.; Mellor, A. L. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod. Immunol. 2004, 61, 67-77.
102. Malachowski, W. P.; Metz, R.; Prendergast, G. C.; Muller, A. J. A new cancer immunosuppression target: indoleamine 2,3-dioxygenase (IDO). A review of the IDO mechanism, inhibition, and therapeutic applications. Drugs Fut. 2005, 30, 897-813.
103. Gaspari, P.; Banerjee, T.; Malachowski, W. P.; Muller, A. J.; Prendergast, G. C.; Duhadaway, J.; Bennett, S.; Donovan, A. M. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J. Med. Chem. 2006, 49, 684-692.
104. Mehta, R. G.; Liu, J.; Constantinou, A.; Thomas, C. F.; Hawthorne, M.; You, M.; Gerhuser, C.; Pezzuto, J. M.; Moon, R. C.; Moriarty, R. M. Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage. Carcinogenesis 1995, 16, 399-404.
105. Park, E. J.; Pezzuto, J. M. Botanicals in cancer chemoprevention. Cancer Metastasis Rev. 2002, 21, 231-255.
106. Vottero, E.; Balgi, A.; Woods, K.; Tugendreich, S.; Melese, T.; Andersen, R. J.; Mauk, A. G.; Roberge, M. Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast. Biotech. J. 2006, 1, 282-288.